Get the Stockscreener App
4.5665
2.12%
0.0865
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is traded at $4.5665, with a volume of 414.85K.
It is up +2.12% in the last 24 hours and down -15.59% over the past month.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
See More
Previous Close:
$4.48
Open:
$4.5
24h Volume:
414.85K
Relative Volume:
0.21
Market Cap:
$1.69B
Revenue:
$9.47B
Net Income/Loss:
$-178.00M
P/E Ratio:
-9.5135
EPS:
-0.48
Net Cash Flow:
$1.01B
1W Performance:
-0.33%
1M Performance:
-15.59%
6M Performance:
-43.45%
1Y Performance:
-27.73%
1-Day Range:
$4.425
$4.595
1-Week Range:
$4.4119
$4.61
52-Week Range:
$3.96
$9.85
Bausch Health Companies Inc Stock (BHC) Company Profile
Name
Bausch Health Companies Inc
Sector
Phone
514-744-6792
Address
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
4.565 | 1.70B | 9.47B | -178.00M | 1.01B | -0.48 |
|
HLN
Haleon Plc Adr
|
11.13 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
171.34 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.86 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.95 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.27 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-24 | Initiated | Raymond James | Mkt Perform |
| Sep-20-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jul-29-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-29-22 | Downgrade | Truist | Buy → Hold |
| Jul-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-13-22 | Resumed | JP Morgan | Overweight |
| Mar-24-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-17-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-22-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-17-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-24-20 | Initiated | Citigroup | Buy |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-22-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-02-19 | Initiated | Goldman | Neutral |
| Oct-25-19 | Initiated | Cowen | Outperform |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Aug-15-19 | Upgrade | TD Securities | Hold → Buy |
| Jul-19-19 | Initiated | Wolfe Research | Outperform |
| Jun-11-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Jan-02-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Nov-05-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-18 | Upgrade | Piper Jaffray | Underweight → Neutral |
View All
Bausch Health Companies Inc Stock (BHC) Latest News
The most oversold and overbought stocks on the TSX - The Globe and Mail
SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Why Is Bausch (BHC) Down 13% Since Last Earnings Report? - Yahoo Finance
Intraocular Lens Market Is Booming So Rapidly 2025-2032 -Bausch - openPR.com
With 51% institutional ownership, Bausch Health Companies Inc. (NYSE:BHC) is a favorite amongst the big guns - Yahoo Finance
Choroidal Neovascularization Market: Insights Into Retinal - openPR.com
Verteporfin Market Projected to Witness Increased UtilizationNovartis, Valeant Pharmaceuticals - openPR.com
Actinic Keratosis Market Poised Boom | Almirall, S.A, Bausch - openPR.com
Bausch Health’s $7.9 Billion Refinancing Transaction - Global Legal Chronicle
Research Analysts Offer Predictions for TSE:BHC Q2 Earnings - Defense World
Equities Analysts Set Expectations for BHC Q3 Earnings - Defense World
Colonoscopy Bowel Preparation Drugs Market Detailed Analysis - openPR.com
Facial Injectable Market Forecasts Report 2025-2030, - GlobeNewswire
Bausch Health Companies IncEnters Agreements With Icahn, Paulson, Kavanagh GroupsSEC Filing - marketscreener.com
Bausch Health and Bausch + Lomb Brief: Cos Have Cited Amendment to Definitive Proxy Statement Relating to 2025 Annual Meeting of Shareholders On May 21, 2025 - marketscreener.com
Bausch + Lomb’s New Board Agreements Announced - TipRanks
Bausch Health Signs New Board Agreements - TipRanks
Bausch Health Companies Inc. (NYSE:BHC) Receives Average Rating of “Reduce” from Analysts - Defense World
Bausch Health Companies (TSE:BHC) Stock Price Up 1.4% – Time to Buy? - Defense World
Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com | FinancialContent - FinancialContent
Balyasny Asset Management L.P. Invests $97,000 in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Global Cataract Surgery Devices Market to grow at a CAGR of 5.50% - openPR.com
Bausch Health Companies Inc. (NYSE:BHC) Stake Lessened by Stifel Financial Corp - Defense World
Bausch, Mylan Settle Patent Suit Over Generic IBS Drugs - Law360
Bausch Health’s CFO Steps In as Interim CAO - TipRanks
India Ophthalmic Devices Market Forecast Report 2025-2033, - GlobeNewswire
Genital Herpes Treatment Market reached US$ 1,143.19 million - openPR.com
Hyperopia Treatment Market Growth, Trends & Opportunities - openPR.com
Bausch Health Elects New Board at Annual Meeting - TipRanks
Bausch Health Announces 2025 Annual Meeting of Shareholder Results - ACCESS Newswire
Bausch Health Annual Meeting: Shareholders Back Board Slate, Executive Pay, and New Stock Plan - Stock Titan
Otoplasty Market Is Booming Worldwide 2025-2032 | Allergan,Bausch Health Companies,Sientra - openPR.com
Bausch + Lomb Brief: Announcing the U.S. Launch of Zenlens CHROMA HOA scleral contact lenses - marketscreener.com
Medical Lasers Market 2025-2032: Emerging Trends, Growth - openPR.com
Oral Mucositis Market Outlook: Trends & Forecast 2024-2031 | - openPR.com
Raymond James Financial Inc. Makes New Investment in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com
Mariner LLC Sells 2,340 Shares of Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Bausch health outlines 2025 guidance with 4-5% revenue and EBITDA growth amid strategic refinancing - MSN
Scar Treatment Market Detailed In New Research Report 2025 | - openPR.com
Bausch Health Companies Inc. (BHC): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey
Bausch Health shares fall 39% following InvestingPro’s overvalued warning By Investing.com - Investing.com
Bausch + Lomb Brief: Says Received European CE Mark Approval for Preloaded LuxLife Full Range of Vision Intraocular Lens - marketscreener.com
Bausch Health (BHC) Data Highlights Reduced Rehospitalization wi - GuruFocus
Bausch Health (BHC) Data Highlights Reduced Rehospitalization with Xifaxan Use | BHC Stock News - GuruFocus
Bausch Health Up 3.5% In US Premarket As Says New Analysis Suggests efficacy of Xifaxan - marketscreener.com
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization - voiceofalexandria.com
Bausch Health (BHC) Target Price Reduced by Raymond James | BHC Stock News - GuruFocus
Bausch Health (BHC) Faces Revised Price Target by Raymond James | BHC Stock News - GuruFocus
Bausch Health price target cut to $8 by Raymond James - Investing.com Nigeria
Dry Eye Syndrome Treatment Market Set to Witness Significant - openPR.com
Bausch Health Companies Inc Stock (BHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.28%
2.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):